These Companies Stands To Benefit The Most From BP's Misfortune

Markit Research have made an analysis of which companies they belive will provide the most significant payouts in the absence of BP’s dividend. BP’s dividend suspension in June meant that investors would forego an estimated £7.8 billion in dividends this year. However, there are significant income opportunities from other stocks, according to the report. Markit expects that dividends from just five companies in the FTSE 100 will constitute over 60% of all those paid between now and BP’s next anticipated dividend in February 2011.

“The fact that recent market rumours suggesting BP might bring forward its planned resumption of dividend payments have received so much media attention is emblematic of its importance to investors and highlights the perceived scarcity of major dividend paying stock alternatives.”

Markit Dividend Research


“Markit is forecasting a yield of over 4% on the FTSE 100 over the forthcoming year. So despite the latest CPI annual inflation figures for August remaining stubbornly high at 3.1% and interest rates not looking likely to increase any time soon, real returns from income stocks appear achievable,” the two analysts Thomas Matheson and Arjun Venu writes in the latest edition of Markit Dividend Research.

.

BP’s dividend suspension in June meant that investors would forego an estimated £7.8 billion in dividends this year. In the absence of this payout, however, there are significant income opportunities from other stocks, according to the report.

“In fact, Markit is forecasting a yield of over 4% on the FTSE 100 over the forthcoming year. So despite the latest CPI annual inflation figures for August remaining stubbornly high at 3.1% and interest rates not looking likely to increase any time soon, real returns from income stocks appear achievable,” Matheson and Venu says:

“Markit expects that dividends from just five companies in the FTSE 100 will constitute over 60% of all those paid between now and BP’s next anticipated dividend in February 2011. This report briefly reviews Markit’s forecasts for each of these companies. For three of these stocks we are expecting dividends to continue to grow, while for the remaining two we expect dividends to remain flat.”

And here they are; the five companies whose shareholders will benefit the most from BP’s misfortune:

.

* Royal Dutch Shell
“The biggest contribution is expected from Royal Dutch Shell, whose payouts will represent just over a quarter of all dividends paid by FTSE 100 companies between now and February. So far in 2010 Shell has managed to maintain its dividend at the 2009 level of $0.42 per quarter and Markit fully expects this to continue for the rest of the year. In addition to cutting costs, Shell has seen positive trends in oil and gas volumes help to improve earnings and cash flow.

* AstraZeneca Plc
“Markit forecasts AstraZeneca’s 2nd interim payment to grow 6.4% to $1.82, which will constitute 12.7% of all dividends on the index. The healthcare behemoth reported strong first half results and raised its full year earnings forecast for the third consecutive time this year. The company also received backing from the FDA advisory panel for potential “blockbuster” drug Brilinta which has boosted the potential future pipeline and eased worries over numerous upcoming patent expires.”

.

* Vodafone Plc

“Vodafone has committed to increasing its dividend by 7% per annum over the next two years and its FY11 interim dividend is expected to amount to a payout of almost £1.7 billion. Markit is forecasting an interim dividend of 2.85 pence per share, which will make up 11.2% of all FTSE 100 dividends between now and February.”

* HSBC Plc
“Despite being cut 39% last year, HSBC’s dividend remains substantial. HSBC’s capital position comfortably exceeds the requirements of Basel III and the company has given guidance that it intends to pay a Q3 dividend of $0.08 in line with its existing policy, amounting to 6.8% of dividends on the index.”

.

* GlaxoSmithKline Plc
“The largest healthcare company in the UK, GlaxoSmithKline has delivered sustained dividend growth throughout the last decade. Markit is forecasting for this to continue with a Q3 dividend of 16.0 pence, up 6.7% from last year. This payment would make up 6.3% of all FTSE 100 dividends. The first half of the year saw sales grow 7% to £14.4 billion and net operating cash flows jump 21% in sterling terms to £4.2 billion, supporting this growth.”

Here’s a short-version of the report.

Advertisements

2 Comments

Filed under International Econnomic Politics, National Economic Politics